Table 1.
Patient characteristics
| Characteristic | Number |
|---|---|
| Patients | 60 |
| Gender (m/f) | 35/25 |
| Median age; range | 55; 21–78 years |
| Median Karnofsky Performance Score; range | 100%; 60–100% |
| WHO grade III anaplastic astrocytoma | 15 |
| IDH mutant | 8 |
| IDH wildtype | 7 |
| MGMT promoter methylated | 12 (80%) |
| Contrast enhancement | 10 (67%) |
| Positive FET uptake* | 12 (80%) |
| WHO grade IV glioblastoma | 45 |
| IDH mutant | 7 |
| IDH wildtype | 38 |
| MGMT promoter methylated | 23 (51%) |
| Contrast enhancement | 44 (98%) |
| Positive FET uptake* | 44 (98%) |
| Biopsy | 21 |
| Partial resection | 10 |
| Complete resection | 29 |
| First-line therapy following resection/biopsy | |
| Chemoradiation with temozolomide 1 | 49 (81%) |
| RT + lomustine-temozolomide 2 | 2 (4%) |
| RT + bevacizumab 3 | 1 (2%) |
| Radiotherapy alone | 8 (13%) |
f female, IDH isocitrate dehydrogenase, m male, MGMT O6-methylguanine-DNA-methyltransferase, RT radiotherapy,
*FET uptake higher than the background activity, visually assessed by two experienced raters
1Treatment according to Stupp et al. [40]
2Treatment according to Herrlinger et al. [45]
3Treatment according to Herrlinger et al. [46]